RxDoctor Payments Data

Christopher Verica

Family · Havertown, PANPI 1386736627

Payments from drug & device makers

$4,560in general payments, 2019–2025

Across 196 payments — averaging $23.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Otsuka America Pharmaceutical, Inc.$1K
  • AbbVie$910
  • Teva Pharmaceuticals USA, Inc.$263
  • Vanda Pharmaceuticals Inc.$223
  • Alkermes, Inc.$212
  • plus $640 from 9 others

What the payments were for

  • Food & beverage$4,43397%
  • Education$1273%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,560 in reported general payments places this provider in the 90th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$23,423
Medicare patients
78
Services billed
301

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate31$110,843
ClozarilClozapine13$33,300
Lurasidone Hcl25$20,942
VraylarCariprazine Hcl13$20,741
ProzacFluoxetine Hcl13$14,729
Divalproex Sodium ErDivalproex Sodium156$11,462
Quetiapine Fumarate216$8,084
Chlorpromazine Hcl29$5,707
Aripiprazole58$4,156
Clozapine42$3,841
Clomipramine Hcl37$3,178
Ziprasidone Hcl55$3,009
Paliperidone ErPaliperidone22$2,800
Asenapine Maleate14$2,624
Perphenazine64$2,489

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$1,195$110,84331 claims
AbbVieVraylar$910$20,74113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,717 family providers in Pennsylvania.

Other family in Havertown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →